SAN DIEGO, United States, December 30, 2024 -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, published a proof-of-concept study of minimal residual disease (MRD) detection in the journal Cancer Medicine. The publication reveals significant advancements in the detection of minimal residual disease (MRD) in patients with liver cancer following radical surgery. The research introduces the SeekInCure test, a novel multi-omics assay that combines circulating tumor DNA (ctDNA) analysis with traditional biomarker alpha-fetoprotein (APF) to enhance prognostic capabilities and improve patient outcomes. Liver cancer remains one of the leading causes of cancer-related deaths worldwide, with high recurrence rates post-surgery. The ability to accurately detect MRD is crucial for timely intervention and personalized treatment strategies. SeekInCure addresses this critical need by utilizing a non-invasive method that assesses multiple biomarkers from peripheral blood samples. The study involved 32 patients diagnosed with liver cancer who underwent radical surgical treatment. Key findings include:

• High Detection Rates: Before surgery, 87.5% of patients exhibited detectable cancer signals in their blood. Post-surgery, 23 out of 32 patients were classified as MRD-negative, showing significantly better overall survival rates compared to MRD-positive patients (p < 0.01).
• Prognostic Value: Patients with undetectable MRD after surgery experienced a remarkable 100% survival rate, highlighting the assay's effectiveness in guiding clinical decisions regarding additional treatments.

"This study represents a significant step forward in our ability to monitor liver cancer patients post-surgery," said Dr. Mao Mao, Founder & CEO of SeekIn. "By integrating ctDNA features with traditional biomarkers like APF, we can provide a more comprehensive assessment of a patient's cancer status, ultimately leading to better management and outcomes." The SeekInCure test stands out for its ease of use and cost-effectiveness, making it a promising tool for routine clinical application. The research underscores the potential of ctDNA-based tumor-naïve MRD detection as a valuable strategy for predicting early recurrence in liver cancer patients. The findings from this study are expected to influence future research directions and clinical practices in liver cancer management, paving the way for improved patient care and survival rates. SeekInCure received CE-IVD Mark in April 2022. The publication can be found at https://doi.org/10.1002/cam4.70511.

About SeekInCure^®

SeekInCure^® is a blood-based test designed for assessing molecular residual disease (MRD) and monitoring cancer recurrence in patients who have undergone radical surgery. This innovative test integrates genomic and epigenetic signals, specifically copy-number aberrations (CNA) and fragment size (FS), along with the quantification of protein tumor markers. By harnessing the power of big data and artificial intelligence, SeekInCure^® generates a Cancer Recurrence Index (CRI) that aims to identify patients at risk of recurrence and those who may benefit from adjuvant therapies.